DARA BioSciences, Inc. Regains Compliance With NASDAQ Bid Price Requirement
2/26/2014 12:51:28 PM
RALEIGH, NC--(Marketwired - February 25, 2014) - DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to therapy and manage side effects arising from cancer treatment, announced today that the Company received notice from the NASDAQ Listing Qualifications Staff that it has regained compliance with the minimum $1.00 bid price per share requirement. The previously disclosed NASDAQ delisting matter related to the Company's bid price compliance is now closed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by